Bioverse Labs

Belkins
Automating species identification using machine learning for AgTech and BioTech industries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

CHEMISTRY42, AN AI SYSTEM FROM INSILICO, HAS BEEN INCORPORATED INTO UCB'S DRUG DISCOVERY PROGRAMMES

Insilico Medicine | March 15, 2021

news image

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and exp...

Read More

CELL AND GENE THERAPY

TUNE THERAPEUTICS LAUNCHES WITH PIONEERING EPIGENOMIC CONTROL PLATFORM TO MASTER GENE NETWORKS, TREAT BROAD RANGE OF DISEASES

Tune Therapeutics | December 03, 2021

news image

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expression up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will. "Genetic medicine is at a tipping point. We now understand that the driving...

Read More

RESEARCH

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

news image

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More

AI

VIVA BIOTECH AND BIOMAP HAVE SIGNED A STRATEGIC COLLABORATION AGREEMENT TO ACCELERATE EARLY DRUG DISCOVERY USING AI TECHNOLOGY

Viva Biotech, BioMap | May 11, 2021

news image

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...

Read More
news image

RESEARCH

CHEMISTRY42, AN AI SYSTEM FROM INSILICO, HAS BEEN INCORPORATED INTO UCB'S DRUG DISCOVERY PROGRAMMES

Insilico Medicine | March 15, 2021

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and exp...

Read More
news image

CELL AND GENE THERAPY

TUNE THERAPEUTICS LAUNCHES WITH PIONEERING EPIGENOMIC CONTROL PLATFORM TO MASTER GENE NETWORKS, TREAT BROAD RANGE OF DISEASES

Tune Therapeutics | December 03, 2021

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expression up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will. "Genetic medicine is at a tipping point. We now understand that the driving...

Read More
news image

RESEARCH

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More
news image

AI

VIVA BIOTECH AND BIOMAP HAVE SIGNED A STRATEGIC COLLABORATION AGREEMENT TO ACCELERATE EARLY DRUG DISCOVERY USING AI TECHNOLOGY

Viva Biotech, BioMap | May 11, 2021

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us